--- title: "Luye Pharma Group (2186) news: convertible notes and buyback" url: "https://aibio.space/companies/luye-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "2186 convertible notes and buyback news: Luye Pharma to issue US$180,000,000 bonds due 2031. Luye Pharma Group Ltd. (HKEX: 2186), China." --- 2186 Luye Pharma Group Ltd. HKEX · China # Luye Pharma Group (2186) news 2186 convertible notes and buyback news Debt Financing · 2026-06-04 ## [Luye Pharma to issue US$180,000,000 bonds due 2031](https://aibio.space/news/luye-pharma-issue-us-180-000-000-bonds-due-2031/) Luye Pharma plans US$180,000,000 of 5.25% convertible bonds due 2031 and a concurrent repurchase of its 6.25% convertible bonds due 2028 at US$1,031.25 per US$1,000 of principal. The announcement says the two transactions may or may not complete. ## Latest Luye Pharma Group news We have not published a story on Luye Pharma Group yet. When there is news, it will appear here. ## Luye Pharma Group at a glance - **Ticker**: 2186 - **Listing**: HKEX - **Country**: China ### Related companies - [Hunan Jiudian Pharmaceutical Co.](https://aibio.space/companies/hunan-jiudian-pharmaceutical/) SZSE: 300705 - [Harbin Gloria Pharmaceuticals Co.](https://aibio.space/companies/harbin-gloria-pharmaceuticals/) SZSE: 002437 - [Shanghai Henlius Biotech](https://aibio.space/companies/shanghai-henlius-biotech/) HKEX: 2696 - [Chengdu Easton Biopharmaceuticals Co.](https://aibio.space/companies/chengdu-easton-biopharmaceuticals/) SSE: 688513 - [Jenkem Technology Co.](https://aibio.space/companies/jenkem-technology/) SSE: 688356 - [Ginwa Enterprise (Group)](https://aibio.space/companies/ginwa-enterprise/) SSE: 600080 - [ApicHope Pharmaceutical Group Co.](https://aibio.space/companies/apichope-pharmaceutical/) SZSE: 300723 - [Beijing Aosaikang Pharmaceutical Co.](https://aibio.space/companies/beijing-aosaikang-pharmaceutical/) SZSE: 002755 ### Also on HKEX - [BioDlink International Company](https://aibio.space/companies/biodlink-international/) 1875 - [HUTCHMED (China)](https://aibio.space/companies/hutchmed-china/) 13 - [TransThera Sciences (Nanjing).](https://aibio.space/companies/transthera-sciences-nanjing/) 2617 - [Shandong Boan Biotechnology Company., Limited.](https://aibio.space/companies/shandong-boan-biotechnology/) 6955 - [Tong Ren Tang Technologies Co.](https://aibio.space/companies/tong-ren-tang-technologies/) 1666 - [PegBio Co.](https://aibio.space/companies/pegbio/) 2565 ## Questions about Luye Pharma Group Has Luye Pharma Group sold convertible notes? Our latest story on this, dated Jun 4, 2026: "Luye Pharma to issue US$180,000,000 bonds due 2031". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/luye-pharma-issue-us-180-000-000-bonds-due-2031/). Does Luye Pharma Group have a share buyback? Our latest story on this, dated Jun 4, 2026: "Luye Pharma to issue US$180,000,000 bonds due 2031". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/luye-pharma-issue-us-180-000-000-bonds-due-2031/). What is the ticker symbol of Luye Pharma Group? Luye Pharma Group Ltd. trades under the ticker 2186 on HKEX. Where is Luye Pharma Group listed? Luye Pharma Group Ltd. is listed on HKEX. Our directory also records these other listings: GETTEX:LUP. Which country or territory is Luye Pharma Group listed under? Our directory records Luye Pharma Group Ltd. under China. What does Luye Pharma Group do? Our directory classifies Luye Pharma Group Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Luye Pharma Group? The ISIN recorded for Luye Pharma Group Ltd. is BMG570071099. Does aibio.space cover Luye Pharma Group? aibio.space lists Luye Pharma Group Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. What is the latest Luye Pharma Group (2186) stock news? Our latest story on Luye Pharma Group, dated Jun 4, 2026: "Luye Pharma to issue US$180,000,000 bonds due 2031". Luye Pharma plans US$180,000,000 of 5.25% convertible bonds due 2031 and a concurrent repurchase of its 6.25% convertible bonds due 2028 at US$1,031.25 per US$1,000 of principal. The announcement says the two transactions may or may not complete. [Source](https://aibio.space/news/luye-pharma-issue-us-180-000-000-bonds-due-2031/). Which companies are similar to Luye Pharma Group? Companies in our directory listed in the same country and business area as Luye Pharma Group: Hunan Jiudian Pharmaceutical Co., Harbin Gloria Pharmaceuticals Co., Shanghai Henlius Biotech, Chengdu Easton Biopharmaceuticals Co., Jenkem Technology Co., Ginwa Enterprise (Group). How can I follow Luye Pharma Group (2186) news? Press Follow on this page to add Luye Pharma Group to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Luye Pharma Group so far, in Debt Financing. ## Investor discussion: Luye Pharma Group Members talk about Luye Pharma Group (2186). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Luye Pharma Group, newest first. Each line links the filing it comes from. 1. 2026-07-06 Listings Trading status: COMPLETION OF EARLY REDEMPTION OF OUTSTANDING US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0706/2026070602089.pdf) 2. 2026-06-11 Financings Share or debt issue: COMPLETION OF CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0611/2026061101345.pdf) 3. 2026-06-11 Financings Share or debt issue: COMPLETION OF ISSUE OF US$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0611/2026061100045.pdf) 4. 2026-06-08 Financings Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0608/2026060801570.pdf) 5. 2026-06-03 Financings Share or debt issue: (1) PROPOSED CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028; AND (2) PROPOSED ISSUE OF US$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0604/2026060400109.pdf) 6. 2026-06-03 Financings Share or debt issue: (1) PROPOSED CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028; AND (2) PROPOSED ISSUE OF USD-DENOMINATED CONVERTIBLE BONDS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0603/2026060302514.pdf) 7. 2026-01-26 Mergers Transaction under the Listing Rules: DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0127/2026012700049.pdf) 8. 2026-01-26 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS AND CONNECTED TRANSACTION FURTHER ANNOUNCEMENT ON THE TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS - COMPLETION OF THE EQUITY TRANSFER. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0127/2026012700045.pdf) 9. 2025-12-28 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1228/2025122800127.pdf) 10. 2025-12-12 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION COMPLETION OF THE ISSUE OF EXCHANGEABLE PREFERENCE SHARES BY A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1212/2025121201704.pdf) 11. 2025-11-20 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION ISSUE OF EXCHANGEABLE PREFERENCE SHARES BY A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1121/2025112100021.pdf) 12. 2025-09-10 Financings Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0910/2025091000623.pdf) 13. 2025-09-09 Financings Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0909/2025090900580.pdf) 14. 2025-08-20 Financings Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0820/2025082000740.pdf) 15. 2025-08-14 Financings Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0814/2025081400998.pdf) 16. 2025-08-01 Financings Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0801/2025080103727.pdf) 17. 2024-12-16 Financings Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1216/2024121601200.pdf) 18. 2024-12-13 Financings Share or debt issue: COMPLETION OF THE ISSUE OF US$50,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1213/2024121301701.pdf) 19. 2024-11-01 Financings Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1101/2024110103527.pdf) ## Press releases Headlines of Luye Pharma Group's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-08-30 HKEXnews [ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0830/2026083000381.pdf) 2. 2026-08-20 HKEXnews [VOLUNTARY ANNOUNCEMENT MRNA VACCINE LY01620 FOR THE TREATMENT OF CERVICAL PRECANCEROUS LESIONS AND HPV-RELATED TUMORS TO ENTER INTO PHASE II CLINICAL TRIAL IN CHINA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001715.pdf) 3. 2026-08-05 HKEXnews [VOLUNTARY ANNOUNCEMENT SUCCESSFUL COMPLETION OF A U.S. BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0805/2026080501863.pdf) 4. 2026-07-06 HKEXnews [COMPLETION OF EARLY REDEMPTION OF OUTSTANDING US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0706/2026070602089.pdf) 5. 2026-06-26 HKEXnews [POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0626/2026062602295.pdf) 6. 2026-06-16 HKEXnews [VOLUNTARY ANNOUNCEMENT THE PHASE 2 CLINICAL TRIAL IN CHINA OF THE GROUP'S NEW DRUG LY03015 (A VMAT2 INHIBITOR/SIGMA-1R AGONIST) FOR THE TREATMENT OF TARDIVE DYSKINESIA HAS ACHIEVED POSITIVE RESULTS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0616/2026061601852.pdf) 7. 2026-06-11 HKEXnews [COMPLETION OF CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0611/2026061101345.pdf) 8. 2026-06-11 HKEXnews [COMPLETION OF ISSUE OF US$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0611/2026061100045.pdf) 9. 2026-06-08 HKEXnews [OVERSEAS REGULATORY ANNOUNCEMENT](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0608/2026060801570.pdf) 10. 2026-06-03 HKEXnews [(1) PROPOSED CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028; AND (2) PROPOSED ISSUE OF US$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0604/2026060400109.pdf) 11. 2026-06-03 HKEXnews [(1) PROPOSED CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028; AND (2) PROPOSED ISSUE OF USD-DENOMINATED CONVERTIBLE BONDS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0603/2026060302514.pdf) 12. 2026-05-29 HKEXnews [NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0529/2026052902940.pdf) 13. 2026-04-20 HKEXnews [VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE U.S. PK BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0420/2026042001352.pdf) 14. 2026-04-15 HKEXnews [VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE CHINA PHASE II CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03017 FOR TREATING ALZHEIMER'S DISEASE-RELATED PSYCHOSIS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0415/2026041501390.pdf) 15. 2026-04-08 HKEXnews [VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S INNOVATIVE DRUG LY03020](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0408/2026040802698.pdf) 16. 2026-03-30 HKEXnews [ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0331/2026033100245.pdf) 17. 2026-01-26 HKEXnews [DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0127/2026012700049.pdf) 18. 2026-01-26 HKEXnews [DISCLOSEABLE TRANSACTIONS AND CONNECTED TRANSACTION FURTHER ANNOUNCEMENT ON THE TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS - COMPLETION OF THE EQUITY TRANSFER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0127/2026012700045.pdf) 19. 2026-01-08 HKEXnews [VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR CLASS 1 INNOVATIVE DRUG RUOXINLIN FOR THE NEW INDICATION OF GENERALIZED ANXIETY DISORDER ACCEPTED IN CHINA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0108/2026010800814.pdf) 20. 2025-12-31 HKEXnews [Terms of Reference for Nomination Committee of the board of directors of the Company](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1231/2025123101887.pdf) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:2186 on TradingView](https://www.tradingview.com/symbols/HKEX-2186/). ## Listing details Luye Pharma Group Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2186, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Luye Pharma Group Ltd. - **Ticker**: 2186 - **Listing**: HKEX - **Country or territory**: China - **Business scope**: Pharmaceuticals: Major - **ISIN**: BMG570071099 - **Other listed symbols**: GETTEX:LUP - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-2186/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/luye-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Luye Pharma Group (2186) news: convertible notes and buyback", 2026-10-31, https://aibio.space/companies/luye-pharma/